AFP and hepatocellular carcinoma: Bevacizumab improves survival and response in HCC compared to sorafenib, with tolerable side effects. In individuals with AFP, ramucirumab is a moderately beneficial second-line treatment, but it comes with severe side effects. ADCs like T-DXd and enfortumab vedotin show promise for HCC, with ongoing clinical trials.